• 217% increase in sales to $29.6 million
• First significant profit result at $4.9 million
• Positive operating cash flow of $6.3 million
• Successful $3 million capital raise

Bioxyne Ltd reported a strong financial performance for the year ended 30 June 2025, with a 217% increase in sales to $29.6 million, primarily driven by medicinal cannabis sales in Australia following the commencement of in-house manufacturing operations in August 2024 and the signing of several major supply contracts. The company reported a first significant profit result of $4.9 million, a significant improvement from the previous year's loss of $13.5 million. The group also generated positive operating cash flow of $6.3 million for the year and invested $2.4 million in plant and machinery to increase manufacturing capacity. Bioxyne completed a successful $3 million capital raise through the issue of 120 million shares at $0.025 each, and 60 million free attaching options with an exercise price of $0.05 and expiry on 26 March 2027. The company also received GMP Compliance Certificates under Mutual Recognition Agreements for Europe, Canada, Singapore, and the United Kingdom, and signed a €3.2 million (A$5.8 million) supply agreement with German companies Farmakem d.o.o. and Adrex Pharmaceuticals GmbH to commence in FY2026. Bioxyne is looking to strengthen its Australian business by broadening its customer base and drive to be the pre-eminent manufacturer of medicinal cannabis products in Australia, while also planning to establish manufacturing operations in the UK and Europe to meet growing demand and opportunities in those regions.

The company reported an underlying operating profit of $5.1 million for the year ended 30 June 2025, a significant improvement from the previous year's underlying loss of $1.4 million.

Bioxyne operates in several high-growth health and wellness markets, including psychedelics, medicinal cannabis, preventative medicine, and novel foods. The company is focused on expanding its pharmaceutical manufacturing and wholesale supply (B2B) of novel medicines, medicinal cannabis, psilocybin, and MDMA, as well as its manufacture and distribution (wholesale, online, and retail, B2C) of consumer health and novel food products. The group is also looking to strengthen its Australian business and establish manufacturing operations in the UK and Europe to meet growing demand and opportunities in those regions.